Dolutegravir Lamivudine and Tenofovir Disoproxil Fumarate tablets are used in combination with other antiretroviral medications to treat HIV (human immunodeficiency virus) infection. This combination medication works by preventing HIV from multiplying and spreading, helping to reduce the amount of HIV in the body. This can decrease the risk of serious HIV-related health problems such as AIDS.
Dolutegravir/lamivudine/tenofovir
Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil. As of 2019[update], it is listed by the World Health Organization (WHO) as the first line treatment for adults, with tenofovir/lamivudine/efavirenz as an alternative. It is taken by mouth.
Side effects may include trouble sleeping, weight gain, and rash. While there are concerns that use during pregnancy results in a 0.2% increased risk of neural tube defects in the baby, this does not rule out its use. Use remains recommended after the first trimester. Use is not recommended in those with kidney problems. The combination is a type of antiretroviral therapy.
It is on the World Health Organization’s List of Essential Medicines. In some countries it is available as a generic medication. It is tentatively approved in the United States as of 2019, full approval is pending expiration of the US patents on dolutegravir (Tivicay) and tenofovir disoproxil (Viread).
Medical uses
As of 2019, it is listed by the World Health Organization (WHO) as the first-line treatment for adults with HIV/AIDS, with tenofovir/lamivudine/efavirenz as an alternative. It may be used in people with both HIV and tuberculosis, however if the person is on rifampicin a larger dose of dolutegravir is needed.
Side effects
Side effects may include trouble sleeping and weight gain. While there are concerns that use during pregnancy results in a 0.2% increased risk of neural tube defects in the baby, this does not rule out its use. Use remains recommended after the first trimester. It should not be used with dofetilide.
Society and culture
Economics
In the developing world it costs about US$75 per year. It is considered more cost effective than tenofovir/lamivudine/efavirenz as of 2019.
References
External links
- “Dolutegravir”. Drug Information Portal. U.S. National Library of Medicine.
- “Lamivudine”. Drug Information Portal. U.S. National Library of Medicine.
- “Tenofovir disoproxil”. Drug Information Portal. U.S. National Library of Medicine.
- “Tenofovir disoproxil fumarate”. Drug Information Portal. U.S. National Library of Medicine.
(Discovery and development)
(Integrase strand transfer inhibitors (INSTI))
(Discovery and development)
| 1st generation | |
|---|---|
| 2nd generation |
inhibitors (RTIs)
| Nucleoside and nucleotide (NRTI) |
|||||
|---|---|---|---|---|---|
| Non-nucleoside (NNRTI) (Discovery and development) |
|
- Abacavir/lamivudine#
- Abacavir/dolutegravir/lamivudine°
- Abacavir/lamivudine/zidovudine
- Atazanavir/cobicistat
- Bictegravir/emtricitabine/tenofovir alafenamide°
- Cabotegravir/rilpivirine
- Darunavir/cobicistat
- Darunavir/cobicistat/emtricitabine/tenofovir alafenamide°
- Dolutegravir/emtricitabine/tenofovir alafenamide
- Dolutegravir/lamivudine°
- Dolutegravir/lamivudine/tenofovir alafenamide°
- Dolutegravir/lamivudine/tenofovir disoproxil°#
- Dolutegravir/rilpivirine
- Doravirine/lamivudine/tenofovir disoproxil
- Efavirenz/emtricitabine/tenofovir disoproxil#
- Efavirenz/lamivudine/tenofovir disoproxil#
- Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
- Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
- Emtricitabine/tenofovir alafenamide
- Emtricitabine/rilpivirine/tenofovir alafenamide
- Emtricitabine/rilpivirine/tenofovir disoproxil
- Emtricitabine/tenofovir disoproxil#
- Lamivudine/nevirapine/stavudine
- Lamivudine/nevirapine/zidovudine
- Lamivudine/raltegravir
- Lamivudine/tenofovir disoproxil#
- Lamivudine/zidovudine#
- Lopinavir/ritonavir#
| Uncoating inhibitors |
|
|---|---|
| Transcription inhibitors | |
| Translation inhibitors | |
| BNAbs | |
| Other | |
| Failed agents |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
°DHHS recommended initial regimen options. ◊Formerly or rarely used agent.
Source: Dolutegravir/lamivudine/tenofovir
Wikipedia
Video about Dolutegravir Lamivudine And Tenofovir Disoproxil Fumarate Tablets Uses
HIV /AIDS {Tenofovir disoproxil fumrate , Lamivudine & Efravirenz tab use & side effects .
Question about Dolutegravir Lamivudine And Tenofovir Disoproxil Fumarate Tablets Uses
If you have any questions about Dolutegravir Lamivudine And Tenofovir Disoproxil Fumarate Tablets Uses, please let us know, all your questions or suggestions will help us improve in the following articles!
The article Dolutegravir Lamivudine And Tenofovir Disoproxil Fumarate Tablets Uses was compiled by me and my team from many sources. If you find the article Dolutegravir Lamivudine And Tenofovir Disoproxil Fumarate Tablets Uses helpful to you, please support the team Like or Share!
Rate Articles Dolutegravir/lamivudine/tenofovir
Rate: 4-5 stars
Ratings: 3413
Views: 81396858
Search keywords Dolutegravir Lamivudine And Tenofovir Disoproxil Fumarate Tablets Uses
1. HIV
2. Antiretroviral
3. ARV
4. Dolutegravir
5. Lamivudine
6. Tenofovir
7. Drug Resistance
8. Adverse Effects
9. Drug Interactions
10. Treatment Outcomes
#Dolutegravirlamivudinetenofovir
